Kornimate/medical-research-clean huggingface dataset:
cognitive training after stroke : effects and mechanisms

Conditions: Stroke

Summary: stroke is a major cause of severe cognitive and physical disability. despite the high and increasing incidence, and large health, economic, social and personal consequences, studies designed to remedy cognitive impairments and improve rehabilitation care following stroke are lacking. a promising line of research have shown that weak electrical current (tdcs) can be a safe, cost-effective, and potent treatment when combined with other rehablitational approaches. the underlying mechanism is assumed that tdcs facilitates neuronal signaling, improving plasticity and facilitating rehablitational outcome. but further research is needed to better understand the mechanisms at hand, and to better evaluate the potential clinical utility. the scope for the current project is to investigate both cognitive and neuronal effects of tdcs in combination with cognitive training , with the ultimate goal to improve current rehabilitational healthcare. to achieve this we will use multimodal mri, eeg, and a comprehensive battery of neuropsychological asessment, to describe and evaluate the effect of tdcs in rehabilitation purposes.

participants are randomly assigned to either active or sham condition, using codes provided by the manufacturer and implemented by an in-house matlab script, pseudo-randomizing participants while maintaining balance in groups of 20. tdcs stimulation is applied at six occasions for each participant, with a minimum of 48 hours between stimulations, aiming at an average of two stimulations per week. stimulation current is1000 μa, stimulation time was 20 min for the active group with a ramp-up time of 120 s and fade-out time of 30 s. the current intensity is limited to 1 ma to limit the risk of adverse events due to the electrical stimulation. the sham stimulation consists of ramp-up followed by 40 s of active stimulation and then fade-out, following factory settings. cognitive training will be done by the computerized working memory training program (cogmed systems ab, stockholm, sweden) consisting of 25 online training sessions. in this study, to increase feasibility, we utilize 17 sessions over a period of three to four weeks, corresponding to approximately five weekly training sessions. on average, we aim at two training sessions combined with tdcs per week with a minimum of one day between each tdcs session. the remaining cct sessions are performed at home. neuropsychological assessments and mri assessments are conducted three times: at baseline 1, after a waiting period of 2-4 weeks (baseline 2, before intervention) and immediately post intervention. self-reported symptoms of fatigue and depression are assessed at five time points, before, during and after completing intervention.

Eligibility criteria:
inclusion criteria: - mr/ct revealing ischemic or hemorrhagic damage (stroke). exclusion criteria: * history of illness or damage to the cns, besides stroke. * \<18 years of age * extensive cognitive decline or dementia * severe psychiatric disorders * substance or alcohol abuse * contraindications for mri.
does simethicone improve operative field in gynecological operations

Conditions: Benign Gynecologic Neoplasm

Summary: mechanical bowel preparation aims to decrease the volume fecal content in the colon, which thereby decreases the total colony count of bacteria, thus, decreasing peritoneal contamination in case of bowel injury, improving the access to the surgical field and facilitating intraoperative bowel manipulation


Eligibility criteria:
inclusion criteria: gynecological operations for benign conditions as hysterectomy, ovarian cystectomy and myomectomy. exclusion criteria: 1. history of allergic reaction to study drugs. 2. more than one scar of previous operation. 3. suspicious of malignancy. 4. psychiatric disorders.
clinical study to evaluate the efficacy of an anti-fungal supplement

Conditions: Candida Systemic; Candida Albicans Infection; Candida Infection

Summary: this is a virtual, double-blind, two-arm, randomized, placebo-controlled clinical trial that will last 12 weeks. participants will take the canxida remove candida cleansing formula rmv or a placebo product daily and complete questionnaires at baseline, week 6, and week 12. candida microbiome testing will be conducted via stool sample at baseline and week 12. the participants will all be blinded to the name of the test brand.


Eligibility criteria:
inclusion criteria: 1. aged between 18-50. 2. female. 3. self-reported recurrent vaginal issues, including: * itching and irritation in and around the vaginal area. * burning sensation during urination or sexual intercourse. * abnormal discharge (e.g. thicker, white, and curd-like in appearance, odorless, or with a mild yeasty smell. * redness and swelling of the vulva and surrounding skin * pain or discomfort in the vaginal area or lower abdomen. * urinary tract infections * vaginal thrush 4. may also experience issues with fatigue, lethargy, and gut or digestive issues. 5. willing to provide two stool samples during the study. 6. willing to adhere to the study protocol. 7. willing to avoid introducing any products or any new forms of regular medication or supplements that target candida overgrowth, gut health, or vaginal health for the duration of the study. exclusion criteria: 1. anyone with severe chronic conditions including oncological conditions, psychiatric disease, diabetes, or other. 2. anyone with known severe allergic reactions or is allergic to the test product or placebo ingredients. 3. currently taking any antibiotics or will be during the trial period. 4. anymore diagnosed with a sexually transmitted disease within the last three months e.g. chlamydia, trichomoniasis, gonorrhea, genital herpes 5. women who are pregnant, breastfeeding, or attempting to become pregnant. 6. having any planned invasive medical procedures during the study period. 7. currently participating in any other clinical study. 8. history of substance abuse. 9. unwilling to follow the study protocol.
cross-over study to prove bioequivalence between two oral formulations of levonorgestrel 1.5 mg

Conditions: Contraceptives, Postcoital

Summary: a single dose, two treatments (postinor-2 and opxion), two periods, two sequences, crossover, randomized, prospective design was chosen with a washout of 14 days between the two study periods. treatment groups are balanced with the same number of male healthy volunteers who were randomly assigned to the study drug administration sequences.


Eligibility criteria:
inclusion criteria: * healthy male volunteers age between 18 and 55 years old with normal vital signs, electrocardiogram (ecg), blood chemistry, liver function profile and urinalysis. exclusion criteria: * history of illnesses or any organic abnormalities that could affect the results of the study. * history of tobacco or alcohol abuse or regular use of recreational or therapeutic drugs. * subjects that have taken any medication within 14 days or that are in an elimination period of less than 7 half-lives (whichever is longest) before study startup.
cbd for dental pain

Conditions: Odontalgia; Toothache

Summary: the purpose of this study is to evaulate cbd as a therapeutic approach for dental pain. eligible subjects presented with emergency dental pain will be give a single dose of epidiolex (fda-approved cbd) or placebo and will be monitored for 3 hours for pain symptoms and psychologic effects.

cbd is a non-psychoactive, non-addictive compound of cannabis that has shown analgesic and anti-inflammatory properties. epidiolex is the only fda-approved oral cbd solution and will be the drug of choice in this study.

Eligibility criteria:
inclusion criteria: * healthy adults 18-75 years old, asa i or ii * permanent tooth with moderate to severe odontogenic pain, i.e. ≥30 on a 100mm vas, * clinical pulpal diagnosis of irreversible pulpitis or pulpal necrosis, and periapical diagnosis of symptomatic apical periodontitis * test negative for recent cannabis use and/or other drugs of abuse including alcohol (urine tests collected at screening visit), and participant * able to understand the forms (english or spanish) and provide informed written consent. exclusion criteria: * asa class iii or iv * patients with hepatic impairment * pregnant or lactating women * patients on drugs metabolized by enzymes that also metabolize cbd (e.g. clobazam, diazepam, topiramate, warfarin) * self-reported prior experience inhaling cannabis (either via smoking or vaporization), use of opioids in the month prior to screening/treatment visit, and/or nsaids or acetaminophen 6 hours prior to treatment * unwilling to participate.

Keywords: cannabidiol (cbd) opioid dose dental pain epidiolex cbd
abdominothoracic muscular tone in functional dyspepsia

Conditions: Dyspepsia

Summary: background. patients with functional dyspepsia report symptoms after eating without detectable cause. a recent proof-of-concept study demonstrated that in healthy subjects, the activity of the abdominal walls influences perception of digestive sensations, specifically, intentional abdominal distension (by a maneuver of diaphragmatic contraction) increased bloating sensation in response to a probe meal. aim. to determine the role of the abdominothoracic muscular activity on symptoms of functional dyspepsia. design. parallel study in dyspeptic patients who have an abnormal somatic response to a probe meal (experimental group), and patients who do not (control group), comparing the effect of abdominophrenic biofeedback on dyspeptic symptoms. the probe meal will consist in stepwise ingestion of a comfort meal (hot ham and cheese sandwich plus orange juice) up to maximal satiation. intervention. a standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the control (active comparator) group. the study outcomes will be measured before, immediately after and at 6 months after biofeedback: 1) clinical symptoms measured by scales during 7 consecutive days. 2) responses to the probe meal: (a) sensations measured by scales; (b) changes in girth by adaptive belts; (c) diaphragmatic position by abdominal ultrasound. relevance. the identification of a pathophysiological mechanism of dyspeptic symptoms could serve as an objective marker for diagnosis and as a target for the development of mechanistic treatments.


Eligibility criteria:
inclusion criteria: * rome iv criteria for functional dyspepsia exclusion criteria: * organic gastrointestinal diseases * obesity * history of anosmia and ageusia * alcohol abuse * eating disorders age- and-sex-matched healthy subjects will be included in parallel to the 30 first patients, to determine the normal values of the response to the probe meal. healthy subjects will not undergo the intervention.

Keywords: functional dyspepsia abdominal distension
efficacy and safety study of bimatoprost sustained-release (sr) in participants with open-angle glaucoma or ocular hypertension

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: this study will evaluate the efficacy and safety of bimatoprost sr in participants with open-angle glaucoma or ocular hypertension. the study includes a 12-month treatment period with an 8-month extended follow-up.


Eligibility criteria:
inclusion criteria: -diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require iop-lowering treatment. exclusion criteria: * previous enrollment in another allergan bimatoprost sr study. * eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye * anticipated need for laser eye surgery in either eye within the first 52 weeks of the study duration * history of glaucoma surgery
a safety and tolerability study of bdb-001 in mild, moderate covid-19 patients

Conditions: COVID-19

Summary: this open, multi-center, multiple ascending dose study was designed to evaluate the safety, tolerability, preliminary efficacy and pk/pd of bdb-001 injection in patients with mild, or general covid-19.


Eligibility criteria:
inclusion criteria: * 18≤ age ≤60, 18 kg/m2 ≤bmi ≤28 kg/m2, male or female; * diagnosed with 2019-ncov infection and classified clinically as mild or general; * agreed not to participate in other clinical studies before completing this study; * with the subject's consent and signed informed consent form by the subject or his/her legal representative. exclusion criteria: * diagnosed with 2019-ncov infection and classified clinically as severe or critical severe; severe pneumonia or acute respiratory distress syndrome, sepsis and septic shock; * the disease would deteriorate significantly within 48 hours judged by the investigators; * immunodeficiency or immune related diseases not suitable for participation judged by the investigators (such as autoimmune diseases, igg4 related diseases, allergic alveolitis, vasculitis, etc); * lymphocyte count \<0.5×109/l; * neutropenia history (neutrophil absolute count was less than 2×109/l in adults), except for infection; * d- dimer \>2000 µg/l; * severe history of lung diseases, such as chronic obstructive pulmonary disease, lung cancer, tuberculosis, etc., history of heart disease: unstable angina pectoris, myocardial infarction, cardiac surgery, cardiac function≥ grade 3 (nyha classification), serious history of liver disease (such as child pugh score ≥grade c), serious renal disease history, such as renal insufficiency (gfr ≤ 15ml/min/1.73m2), etc; * the subjects used the following drugs within 2 weeks (including 2 weeks) before screening: 1. calcineurin inhibitors (such as cyclosporin and tacrolimus); 2. proliferation inhibitors (such as everolimus, sirolimus, etc); 3. anti-metabolic agents (such as mycophenolate mofetil, mycophenolic acid, purine sulfate, etc); * pregnant or lactating women.
evaluation of the effects of chemotherapy on the uptake and retention of carbon 11 methionine in prostate cancer patients

Conditions: Prostate Cancer

Summary: the purpose of this study is to better understand a new type of radiology test called positron emission tomography (pet) with carbon 11 methionine to determine which patients have a beneficial effect from anti-cancer therapy with the drug docetaxel.

in the week before the patients first dose of chemotherapy they will receive a c11 methionine pet scan which takes about 90 minutes. c11 methionine is a radioactively labeled amino acid that is given to the patient intravenously. eighteen to twenty days after the patients first dose of docetaxel chemotherapy, they will have another c11 methionine pet scan which is identical to the first scan. at the end of three cycles of docetaxel chemotherapy (about 2 and 1/2 months on study) another c11 methionine pet scan will be done. the pet scans will show how well the tumor is taking up methionine.

Eligibility criteria:
inclusion criteria: * metastatic hormone-refractory prostate cancer patients who are planned to begin every 3-week docetaxel chemotherapy * progression after androgen deprivation therapy * serum testosterone \< 50ng/ml * 18 years of age or older exclusion criteria: * prior taxane therapy

Keywords: prostate cancer hormone-refractory prostate cancer pet scan c11-methionine positron emission tomography
network support for alcohol treatment 2

Conditions: Alcohol Consumption

Summary: the network support project is part of an ongoing effort to improve treatment for alcohol dependent patients. the network support project is designed to help patients change their social network from one that reinforces drinking behavior to one that reinforces sobriety. 160 patients will be assigned to one of two treatments. each of the treatments will last 12 weeks. the first is a network support (ns) treatment designed to help patients develop new acquaintances and social networks. it is expected that alcohol dependent patients will benefit from increasing their contact with non-drinking people. this ns condition will be compared to a packaged cbt program for alcoholics (pcbt) that is designed to teach a number of skills to help people stop drinking, but does not address social networks per se. in order to better understand what is happening to the investigators patients, the investigators will be using daily computerized telephone calls to ask about people's experiences. this will be done both before and after treatment. patients will also be asked to participate in follow-up interviews every 3 months for 2 years following the end of treatment.


Eligibility criteria:
inclusion criteria: * 18 yo * meets diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) criteria for alcohol dependence exclusion criteria: * acute medical or psychiatric problems that require inpatient treatment (e.g., acute psychosis, or suicide/homicide risk) * reading ability below the fifth grade level * lack of reliable transportation to the treatment site, or excessive commuting distance * inability to understand english

Keywords: alcohol dependence network support cognitive-behavioral treatment relapse prevention consequences of drinking social network development
extubation strategies in neuro-intensive care unit patients and associations with outcome.

Conditions: Brain Injuries

Summary: rationale prolonged mechanical ventilation (mv) is common in patients with severe brain injury (bi). guidelines for the management of extubation are largely lacking for patients with bi, and the role of tracheostomy is highly uncertain. more important, data on practice of management of extubation is yet underreported, as is the use of tracheotomy in this specific subset of critical care patients. objective the objective of this prospective observational study is to describe the management of extubation and tracheostomy in intensive care unit (icu) patients with bi. the aim is to describe the incidence of extubation failure and the rate of tracheostomy. study design the "extubation strategies in neuro-intensive care unit patients, and associations with outcomes (enio)" is an observational multicentre international cohort study. study population the investigators will include patients undergoing bi, with an initial glasgow coma score ≤ 12 and with a delivered duration of mechanical ventilation (mv) ≥ 24 hours at icu admission. the inclusion period will last 6 months in total, and each centre is expected to include at least 24 patients during this period. with over 60 icus participating worldwide, we expect to include 1500 patients. main parameters parameters to be collected include: general neurological management, ventilatory management, general icu complications, specific data on extubation and tracheostomy, general in-icu outcomes and in-hospital mortality. nature and extent of the burden and risks associated with participation because of the observational design of the study using routinely collected data, there is no additional burden for the patient. collection of data from icu charts and/or (written or electronic) medical records systems bears no risk to the patients.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years' old * patients admitted in a icu for a central neurological pathology, listed as follows, with estimated or clinically evaluated glasgow coma score ≤12 before endo-tracheal intubation, with anomaly on brain ct-scan and requiring effective invasive mechanical ventilation ≥ 24 hours are eligible to the study: * traumatic brain injury * aneurysmal subarachnoid haemorrhage * intra-cranial haemorrhage * ischemic stroke * central nervous system infection (abscess, empyema, meningitides, encephalitis...) * brain tumour * patient with an attempt of extubation and/or performance of a tracheostomy exclusion criteria: * patients \< 18 years' old * patients with ongoing pregnancy * patients with spine cord injury above t4 * resuscitated cardiac arrest * withdrawal of life-sustaining treatment (wlst) in the first 24 hours
prenatal diagnosis of the fetal esophageal or intestinal atresia

Conditions: Antenatal Management of the Fetal Gastrointestinal Atresia

Summary: aim- to investigate how prenatal diagnosis of fetal esophageal or intestinal atresia impacts obstetric and neonatal outcomes. methods- this was a retrospective cohort study at a single center. the study population comprised 51 consecutive pregnancies, including 29 mothers (57%) and their fetuses affected by prenatally diagnosed fetal esophageal or intestinal atresia, and 22 mothers (43%) and their babies with postnatally diagnosed fetal esophageal or intestinal atresia.

aim- to investigate how prenatal diagnosis of fetal esophageal or intestinal atresia impacts obstetric and neonatal outcomes. methods- this was a retrospective cohort study at a single center. the study population comprised 51 consecutive participants, including 29 mothers (57%) and their fetuses affected by prenatally diagnosed fetal esophageal or intestinal atresia, and 22 mothers (43%) and their babies with postnatally diagnosed fetal esophageal or intestinal atresia.

Eligibility criteria:
inclusion criteria: * all pregnancies affected by fetal esophageal, duodenal or intestinal atresia referred to our prenatal diagnosis unit * all newborns managed for such atresia in our unit of pediatric surgery exclusion criteria: * termination of pregnancy, * stillbirth, * the false positive cases
immune regulation in multiple sclerosis: the effect of glatiramer acetate on microrna expression in antigen-presenting cells

Conditions: Multiple Sclerosis

Summary: micrornas regulate gene expression. the abnormal expression of micrornas has been reported in many human diseases. the purpose of this pilot study is to determine if microrna expression is changed in untreated and glatiramer acetate-treated patients with multiple sclerosis.

micrornas regulate gene expression. the abnormal expression of micrornas has been reported in many human diseases. the purpose of this pilot study is to determine if microrna expression is changed in untreated and glatiramer acetate-treated patients with multiple sclerosis. the expression of microrna will be analysed in cell subsets separated from peripheral blood mononuclear cells.

Eligibility criteria:
inclusion criteria: 18-60 year-old healthy subjects or patients with rrms/cis exclusion criteria: 1. any treatment with steroids in the last 30 days prior to the blood draw or any immunosuppressive or disease-modifying treatment (dmt) other than glatiramer acetate in the last 90 days 2. presence of other disorders that may be associated with immune-deficient or autoimmune process (e.g., hiv, lymphoma, lupus) or demyelinating disease other than ms (e.g., lyme, b12 deficiency) 3. pregnancy 4. intermittent or unilateral constant assistance (cane, crutch, brace) required to walk about 100 meters with or without resting (expanded disability status scale (edss) score greater than 5.5)